We previously generated a murine-human anti-VEGFR2 chimeric Fab (cFab), named FA8H1, which has the potential to treat VEGFR2-overexpressing solid tumors. Here, we investigated whether FA8H1 can be used as a carrier in molecularly targeted therapy in HCC xenograft models. FA8H1 was labeled with 131 I, and two HCC xenograft models were generated using BEL-7402 (high VEGFR2-expressing) and SMMC-7721 (low VEGFR2-expressing) cells, which were selected from five HCC cell lines. The biodistribution of 131 I-FA8H1 was determined in both models by Single-Photon Emission Computed Tomography and therapeutic effects were monitored in nude mice bearing BEL-7402 xenografts. Finally, we determined the involvement of necrosis and apoptotic pathways in treated mice using immunohistochemistry. Human liver cancer, particularly hepatocellular carcinoma (HCC), is the sixth most common neoplasm worldwide and the third highest cause of cancer deaths worldwide 1 . Most HCC patients are diagnosed at an advanced stage, when traditional treatments are not effective 2, 3 . Despite the advances in surgery, liver transplantation and systemic chemotherapy, the survival rate of HCC patients has not improved much over recent decades 2, 3 . Monoclonal antibodies (mAbs) can be used for molecular imaging as well as cancer-specific vehicles to deliver therapy to the tumor site 4, 5 . However, the use of murine mAbs is limited in the clinic because of their high immunogenicity, large molecular weight, and the risk of human anti-mouse antibody (HAMA) responses 6, 7 . Murine-human chimeric Fab (cFab) was prepared from a murine antibody. cFab offers several advantages over whole murine IgG: first, molecular weight of murine-human chimeric Fab (cFab) is approximately 50 kDa and only one-third of the size of full-length
I-anti-VEGFR2 cFab has the potential to be used for molecularly targeted treatment of HCC overexpressing VEGFR2.
Human liver cancer, particularly hepatocellular carcinoma (HCC), is the sixth most common neoplasm worldwide and the third highest cause of cancer deaths worldwide 1 . Most HCC patients are diagnosed at an advanced stage, when traditional treatments are not effective 2, 3 . Despite the advances in surgery, liver transplantation and systemic chemotherapy, the survival rate of HCC patients has not improved much over recent decades 2, 3 . Monoclonal antibodies (mAbs) can be used for molecular imaging as well as cancer-specific vehicles to deliver therapy to the tumor site 4, 5 . However, the use of murine mAbs is limited in the clinic because of their high immunogenicity, large molecular weight, and the risk of human anti-mouse antibody (HAMA) responses 6, 7 . Murine-human chimeric Fab (cFab) was prepared from a murine antibody. cFab offers several advantages over whole murine IgG: first, molecular weight of murine-human chimeric Fab (cFab) is approximately 50 kDa and only one-third of the size of full-length Scientific RepoRts | 5:10660 | DOi: 10.1038/srep10660
IgG. Secondly, cFab reduces the HAMAs responses as it is prepared by recombining whole murine variable regions with human constant regions [8] [9] [10] [11] [12] . Many cFabs have been studied under pre-clinical or clinical development, and have become one of the most prolific drug classes in oncology [13] [14] [15] . We previously produced a high-affinity murine anti-vascular endothelial growth factor receptor 2 (VEGFR2) mAb (A8H1) using mouse hybridoma technology 16 , and constructed anti-VEGFR2-cFab (FA8H1) containing the variable region from A8H1 and the constant region from human IgG. The chimeric Fab maintained the specificity for the VEGFR2 antigen 17 . VEGFR2 plays an important role in angiogenesis in a wide variety of malignancies [18] [19] [20] , such as HCC 21 . Our previous study confirmed the prognostic significance of VEGFR2 overexpression in HCC 22 . VEGFR2 has also been investigated as an anticancer target [23] [24] [25] . In fact, one VEGFR2 mAb, ramucirumab (IMC-1121B) is currently being tested in the treatment of human cancer 26, 27 . Radioimmunotherapy (RAIT) involves the use of mAbs in combination with therapeutic radionuclides, which have been increasingly used in the clinical setting 28, 29 . For example, both yttrium-90-ibritumomab tiuxetan (Zevalin) and 131 I-labeled Tositumomab (Bexxar) are FDA-approved to treat non-Hodgkin's lymphoma (NHL) [30] [31] [32] . In this study, we investigated the therapeutic efficacy of radioiodinated anti-VEGFR2-cFab (FA8H1) on human HCC xenografts. We determined the biodistribution of 131 I-labeled FA8H1 and its therapeutic effects in vivo, and the hematological toxicities from the iodinated antibody were assessed. Finally, we determined the involvement of necrosis and apoptotic pathways in the therapeutic effects of 131 I-labeled FA8H1.
Materials and methods
Cell Lines and Culture. Five HCC cell lines, BEL-7402, QCY-7701, SMMC-7721, HepG-2 and SK-HEP-1, were purchased from the cell bank of the Chinese Academy of Science in Shanghai, China. They were cultured in DMEM medium (Gibco, Invitrogen, USA) containing 10% fetal bovine serum (FBS) at 37 °C and 5% CO 2 .
Fluorescence-Activated Cell Sorting (FACS).
HCC cell lines were treated with FA8H1 at 20 μ g/ml overnight at 4 °C. After washing with phosphate-buffered saline (PBS), they were incubated with 0.01% rhodamine-conjugated anti-human Fab antibody (Rockland, USA). Cells were then centrifuged and washed, and subsequently analyzed on a BD FACS Calibur using the Cell Quest program. Background staining was obtained by replacement of the primary antibody with the sonicated supernatant of E. coli TOP10F´1 7 . And the experiment was repeated by displacement of the primary antibody with PBS as a negative control which was consistent with the control using the sonicated bacterial supernatant.
Radiolabeling of Anti-VEGFR2-cFab. Murine-human chimeric anti-VEGFR2-Fab (FA8H1) was previously generated in our laboratory 17 . The chloramine-T method 33 Louis, MO) and incubated for 10 minutes at room temperature. Then the mixture was separated from free iodide by passing over an equilibrated PD-10 desalting column (GE, Niskayuna, NY, USA). The labeling efficiency was determined in a Perkin Elmer 1470 Automatic Gamma counter (Fremont, CA, USA). The radiochemical purity (RCP) of 131 I-FA8H1 was assessed by a trichloroacetic acid (TCA) assay, as described elsewhere 33, 34 , and the stability of 131 I -FA8H1 in vitro was determined by incubating of the 131 I-FA8H1 in murine blood with heparin at 37 °C for 24 h.
Immunoreactivity of Radiolabeled Anti-VEGFR2-cFab. HCC cell lines were harvested by scraping using TrypLE Express (Invitrogen, USA) and washed with PBS (pH 7.4). A total of 2 × 10 6 cells were re-suspended in 1 ml PBS (pH 7.4) containing 0.2% BSA, and incubated with 10 μ g/ml 131 I-FA8H1 in a 37 °C water bath for 1 h. Cells were washed twice and spun at 2,000 rpm for 10 min. The radioactivity of the pellets was then read by a gamma reader. Same number of cells were incubated with the presence of a 200-fold molar excess of 131 I-labelled unrelated cFab (human-murine chimeric antibody against protective antigen of Bacillus anthracis, which was prepared in our lab) 35 to obtain the nonspecific binding as the blank (NSB, nonspecific binding). The assay was repeated three times. Biodistribution Studies. Total 36 tumor-bearing nude mice with high VEGFR2 expression were randomly divided into six groups (n = 6/group) when tumors had reached 0.5-0.8 cm in diameter as measured by external caliper measurement. Animals were injected with 10 μ Ci 131 I-FA8H1 through the tail vein under light inhalation anesthesia. Then whole-body images of each mouse were acquired at 6, 12, 24 and 48 h post-injection by Single-Photon Emission Computed Tomography (SPECT, Skylight; Philip, Amsterdam, the Netherlands). The mice were sacrificed at 1, 6, 12, 24, 48, and 72 h, and tumors and tissues (blood, brain, heart, liver, spleen, kidney, and lung) were removed for measurement of 131 I-FA8H1 accumulation using a gamma counter. The results were calculated as a percentage of the injected dose per gram of tissue (%ID/g) [34] .
Imaging studies. Both (n = 6/group) HCC xenograft models, were used on imaging study when the tumor's dimension achieved 1.0 cm in size. Prior to the imaging session, mice were anaesthetised with 13 mg/kg xylazine and 87 mg/kg ketamine. In brief, each mouse was injected with 200 μ Ci I along with 300 μ g unlabeled FA8H1 and PBS in the same volume. Tumor volumes were measured once a week for 42 days and calculated according to the following equation: tumor volume (TV) = π /6 × a × b2, where a is the longest diameter, and b is the shortest diameter, as we described elsewhere 36 . These animals were sequentially killed by CO 2 asphyxiation. Tumors were removed, weighed, and stored for further use.
Hematoxylin-Eosin (H&E) Staining. Tumor were formalin-fixed and paraffin-embedded. All sections were cut to 4 μ m on a manual rotary microtome (Leica RM2235, Germany). The sections for H&E were stained by an Automated Slide Stainer (Leica ST5020, Germany) and cover slipped with a Robotic Coverslipper (Leica CV5030, Germany). The extent of tumor necrosis was divided into four grades, including without or including illegibility necrosis (-), spotty necrosis (+ ), small schistic necrosis (+ + ) and big schistic necrosis (+ + + ).
Immunohistochemistry (IHC) and Scoring. Deparaffinized sections (4 μ m-thick) from paraffin blocks were separately stained as we described previously 37, 38 using the following primary antibodies: rabbit polyclonal to Fas Ligand (1:1000, ab15285, Abcam, USA) and rabbit polyclonal to Caspase 3 (1:1000, ab4051, Abcam, USA). Secondary antibody was Envision goat anti-rabbit HRP (DAKO, USA). The evaluation of the immunostaining of these proteins was blinded to the pathologists (Huang J and Feng Z) by an independent observation simultaneous design. The sum of the percentages and intensity scores was used as the final staining score, as described previously 22 . Statistical Analysis. Using the STATA V.9.0 Statistics package(version 9.0; Stata Corp, College Station, TX, USA), the analysis of variance (ANOVA) and the least significant difference (LSD) method were used to assess changes in tumor weight and tumor volume. Mean ± SD was calculated for each group. The degree of tumor necrosis and the disparate expression of FasL or caspase 3 in tumor tissues were examined using the Kruskal-Willis test. For all analyses, data were analyzed using STATA, and a P value < 0.05 was considered to be statistically significant. (Fig. 1a) .
Results
Binding and Immunoreactivity of Radioiodinated Antibody. The radiochemical purity of the labeled antibody was found to be > 95.5%, and the specific activity of 131 I-FA8H1 ranged from approximately 1.0 to 1.5 mCi/mg. Radiopharmaceutical quality control was confirmed by layer chromatography. The amount of free nuclide in blood fell from 98 to 97.5% in 24 h at 37 °C. Specific binding between 131 I-FA8H1 and native VEGFR2 in HCC cells was confirmed with a gamma counter by measuring binding between the cells and 131 I-FA8H1, representing the total binding, versus a radiolabeled unrelated cFab, representing non-specific binding (Fig. 1b) . The specific binding of the FA8H1 antibody was substantial after comparing total binding and non-specific binding, especially when the fact that a 200-fold molar excess of radiolabeled non-specific antibody was used is taken into account. These results were consistent with the data obtained by flow cytometry analysis and previous western blotting data for VEGFR2 in HCC cell lines 22 . BEL-7402 and SMMC-7721 had the highest and lowest native VEGFR2 expression of the five HCC cell lines, respectively, and were thus chosen as the suitable cell lines for subsequent experiments.
Biodistribution Studies in Vivo. As shown in Fig. 1c , radioactivity levels were greatly reduced in blood and other viscera, and elevated to the highest levels (18.31% (± 1.31)) in tumors at 24 h. With time, blood activity and levels (9.57% (± 0.46)) in other normal tissues presented discontinuous and weaker expression, while good retention of activity in tumors could be detected at 72 h (F = 5.33, P < 0.0001). The biological half-life of the 131 I-FA8H1 in the BEL-7402 xenograft was estimated to be 120 h from this portion of the decay curve.
Effect of

131
I-FA8H1 in vivo imaging on HCC model. SPECT images were acquired for individual mice bearing BEL-7402 HCC model and SMMC-7721 HCC model, which separately had high and low VEGFR2 expression levels. Since injected with the 131 I-FA8H1, the tumor in the left hindlimb of these mice was visible within 6 hours after tracer injection in the two kinds of tumor models. As the metabolism of these animals, the image of brain and other viscera get more and more down-expression along with time passing. At 24 h post-injection, the tumor in the higher VEGFR2 expression of BEL-7402 HCC xenograft was easily seen, and the representative patterns were listed in Fig. 2a , which supported the consequence of biodistribution in vivo study in some degree.
Changes in Tumor Volume and Weight in the HCC Xenografts.
To reduce the number of animals used, we focused this experiment on mice bearing BEL-7402 tumors which showed the highest expression level of VEGFR2 among the five HCC cell lines tested. As shown in Fig. 2b,c , no anti-tumor activity was observed in the PBS control group. Prominent inhibition of tumor volume and weight with high 18 .31% (± 1.31) of injected activity was found in the tumors at the peak, whereas blood activity had already fallen to 9.57% (± 0.46) and levels in other normal tissues were even lower. At 48 h, there was good retention of activity within tumors at 17.05% (± 1.28) of injected activity, whereas blood activity was further fallen to 4.28% (± 0.22).
Scientific RepoRts | 5:10660 | DOi: 10.1038/srep10660 dose of 300 μ Ci 131 I-FA8H1 was observed, and remarkable growth-inhibitory effects could be seen in the 300 μ g FA8H1 alone group or the 300 μ Ci 131 I alone group as compared with the PBS control group. No significant difference was found in tumor growth between the 300 μ g FA8H1 alone group and the 300 μ Ci 131 I group. Furthermore, the anti-tumor result was significantly enhanced with the elevated dose of 131 I-FA8H1 (100, 200, and 300 μ Ci) during the process of tumor growth (F = 9.88, P < 0.001, tumor volume; F = 701.45, P < 0.001, tumor weight), the detail could be seen in the Fig. 2b,c. Histopathologic Tumor Necrosis in HCC Tissue. The morphological changes characteristic of tumor necrosis could be easily observed using H-E staining. As shown in Table 1 and Fig. 3a , the category and the extent of necrosis were disparate with distinct therapeutics. Although necrosis was not significant in the PBS group, fibrinoid necrosis was identified in the FA8H1 alone group. Moreover, coagulative 
Effects of Treatment through Apoptotic Pathways. The expression of two apoptosis indicator
proteins, FasL and caspase 3, in the tumor tissues was evaluated by immunohistochemical staining (Fig. 3a,b) . Compared with the HCC tissue of the PBS group, FasL and caspase 3 expressions in the other five groups were both increased, especially in the three 131 I-FA8H1 groups (P < 0.001; Table 2 ).
Discussion
In targeted therapy to human malignant tumors, the ideal therapeutic drug only affects tumor cells, having no influence on normal cell proliferation, and does not cause toxicity in vivo 39 . VEGFR2 was initially considered to be one of the most important targets in anticancer treatment, and its targeting could meet the above requirements 19, 40 . Our previous work demonstrated that the VEGFR2 expression in liver cancer was much higher than in normal liver tissues, and this high VEGFR2 expression was associated with the poor outcome of these patients 22 . Moreover, we established an active murine-human chimeric Fab antibody (FA8H1), which is added to the list of potential therapeutic agents against solid tumors overexpressing VEGFR2 17 .
In the current research, the chimeric Fab antibody was radioiodinated with 131 I to investigate its therapeutic efficacy. A minimal biodistribution study was performed for this experiment prior to the therapy studies to confirm selective tumor localization and retention. The biodistribution study showed that tumors with high VEGFR2 expression could be clearly detected at appropriate time points and that the retention of the I-labeled chimeric anti-VEGFR2 Fab was determined. To our knowledge, these observations were seldom made in previous studies 19, 42, 43 that reported the anti-tumor role of radionuclide labeled mAbs. There were some limitations of this study. First, our results lack clues regarding the detailed molecular mechanism involved in the binding of the anti-VEGFR2 antibody and VEGFR2 antigen on the tumor cell surface. Moreover, the side-effects and toxicity issues were ignored in our present investigation. Furthermore, following observations of neutralizing effectiveness of FA8H1 in the HCC animal model, we did not perform further experiments to verify and expand the neutralizing antibody. In addition, the biodistribution and RAIT were studied in mice, but it remains to be determined whether those conclusions will also apply to human patients with HCC. Also in this investigation, we mainly focused on the cancer cells in the tumors; since VEGFR2 plays an important role in the formation of tumor angiogenesis, we did not examine the changes in new blood vessels formation in tumors resulting from the targeted treatment. Finally, it remains to be determined if FA8H1 is specific to HCC or whether it plays a similar functional role in other human malignancies.
Since we have established that VEGFR2 expression is low in adult human liver 22, 44 , and that HCC can be treated in a mice model via the caudal vein, we believe model in mice. Thus further studies are needed to determine the mechanisms involved in the neutralizing effect of FA8H1 on HCC tumorigenesis.
